The FDA has just approved an oral suspension therapy, Relyvrio from Amylyx Pharmaceuticals, for ALS (amyotrophic lateral sclerosis or Lou Gehrig’s disease). Relyvrio joins a surprisingly
A few weeks ago, a press release from Shields Health announced that it had obtained accreditation from URAC…… not as a dispensing specialty pharmacy but,
We reviewed a report from the Office of Disease Prevention and Health Promotion, a part of the U.S. Department of Health and Human Services some
It’s been a rocky road for CVS of late. In July, CVS was assessed a multi-million $ fine in an arbitration case filed by a small
We’ve written numerous times about value-based contracting (VBC)….. including earlier this week. When it emerged a few years ago there was much hope that VBC
Value Based Contracting….. the great hope for fixing many of the disparities in access and payment for pharmaceuticals, especially those that cost a boat load of
Several recent reports have touched on biosimilars and today we’ll offer up some new data that shows how pricing is being impacted. A new university
The FDA recently approved a new subcutaneously administered therapy, Tezspire (tezepelumab-ekko) from AstraZeneca AB and Amgen, as an add-on maintenance treatment used to improve severe
The answer to whether biosimilar fever has arrived is ….. ‘almost’….. if one believes the comments from CIGNA in the article below. CIGNA is bullish on
Today we offer a review of a recent report issued by the American Hospital Association (AHA) wherein the association excoriates payer practices that ‘force’ the
